An observational study of stage III NSCLC in Taiwan showed that upfront chemoradiotherapy with subsequent EGFR-TKI provided a longer survival time compared to upfront EGFR-TKI in patients with a stage III unresectable EGFR-mutant NSCLC [68]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.